Table 5.
Antiangiogenic targets
| Endogenous inhibitors | Angiostatin |
| Endostatin | |
| Thrombospondin-2 | |
| Interleukin-4, interleukin-13 | |
| Platelet factor-4/CXCL4 chemokine | |
| Exogenous inhibitors | Classical disease-modifying antirheumatic drugs |
| Anti-tumor necrosis factor biologics | |
| Thalidomide | |
| Fumagillin analogs | |
| Vascular endothelial growth factor inhibitors | |
| Hypoxia-inducible factor heterodimer inhibitors | |
| Angiopoietin-1/Tie2 inhibitors | |
| αVβ3 integrin inhibitors | |
| Microtubule destabilizers (for example, paclitaxel) | |
| Others (for example, glitazones) |